GeoVax_logo_tag_Reg.jpg 

GeoVax Labs, Inc.
1900 Lake Park Drive, Suite 380
Smyrna, GA 30080

https://www.geovax.com/

You Might Also Like...

Key Points About GeoVax

Blogs: GOVX

Recent News Releases

GeoVax Provides Update on its Zika Vaccine Development

GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, is delivering an updated presentation of results from...Read more

GeoVax Presents Zika Vaccine Data at Scientific Conference

GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, gave a comprehensive presentation of results from studies...Read more

GeoVax Presents Preliminary Data for Cancer Vaccine

GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will be presenting preliminary results from studies of...Read more

GeoVax to Present at Upcoming Immuno-Oncology Conference

GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced today that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will give two talks at the Immuno-Oncology Summit...Read more

GeoVax Labs, Inc. (GOVX-OTC)

GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical-stage biotechnology company developing preventative and therapeutic human vaccines against infectious diseases and cancer. The Company’s unique and patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology is the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs in a vaccinated person mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear, while maintaining the safety characteristics of a replication-defective vector. GeoVax is currently focused on developing vaccines against human immunodeficiency virus (HIV), Zika virus (ZIKV), hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), and malaria. The Company also has programs to develop a vaccine to treat chronic Hepatitis B virus (HBV) infection and to apply its MVA-VLP technology to cancer immunotherapy (immuno-oncology). GeoVax believes its technology and development expertise is complementary to a range of other human diseases for which there is an unmet medical need, and accordingly, has plans to expand its pipeline.

* The Corporate Snapshot was last updated on June 19, 2017.

Latest Research

GeoVax_EIO_Cover_Image.png

Download GeoVax Report 

06-15-17

Key Points About GeoVax

Blogs: GOVX